Domestic price of Ribociclib succinate tablets

Ribociclib (Ribociclib) is one of the most selective CDK4/6 inhibitors and has dose-dependent anti-tumor activity in many preclinical models. It inhibits tumor cell growth by blocking cells at the G1 checkpoint, thereby preventing tumor cell proliferation.

Inhibition of cyclin-dependent kinases4 and 6 (CDK4/6) may provide protection against oncogenic processes in specific tissue types. For example, based on studies in knockout mice, CDK4 is not required for normal mammary tissue development but is required for Ras-induced mammary tumor growth, suggesting a potential therapeutic window for less toxic treatments. Riboxiclib is an orally bioavailable, highly selective inhibitor of CDK4/6 kinase with inhibitory IC50 concentrations in the low nanomolar range. After oral administration, reboxiclib is rapidly absorbed with a mean Tmax of 1-5 hours. Due to accumulation, plasma concentrations increased approximately 2-3 times from Day 1 of Cycle 1 to Days 18/21 of Cycle 1, reaching a steady state approximately on Day 8 based on trough concentrations after repeated daily dosing.

The original drug Riboxil is already on the market in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. Riboxil succinate tablets are sold under the name of the drug, and its trade name is Kaililong. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.